Bortezomib enhances dendritic cell (DC)–mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications
Top Cited Papers
Open Access
- 1 June 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 109 (11) , 4839-4845
- https://doi.org/10.1182/blood-2006-10-054221
Abstract
Most anticancer chemotherapies are immunosuppressive and induce nonimmunogenic tumor cell death. Bortezomib, a specific inhibitor of 26S proteasome, has shown clinical activity in several human tumors, including myeloma. Here we show that the uptake of human myeloma cells by dendritic cells (DCs) after tumor cell death by bortezomib, but not γ irradiation or steroids, leads to the induction of antitumor immunity, including against primary tumor cells, without the need for any additional adjuvants. The delivery of activating signal from bortezomib-killed tumor cells to DCs depends on cell-cell contact between DCs and dying tumor cells and is mediated by bortezomib-induced exposure of heat shock protein 90 (hsp90) on the surface of dying cells. The combination of bortezomib and geldanamycin (an hsp90 inhibitor) leads to greater apoptosis of tumor cells but abrogates their immunogenicity. These data identify drug-induced exposure of endogenous heat shock proteins on the surface of dying cells as a mechanism of immunogenic death of human tumors. Specific targeting of bortezomib to tumors may enhance their immunogenicity and the induction of antitumor immunity.Keywords
This publication has 29 references indexed in Scilit:
- Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cellsProceedings of the National Academy of Sciences, 2005
- Immune Response Against Dying Tumor CellsPublished by Elsevier ,2004
- CD8 + T Cell Cross-Priming via Transfer of Proteasome SubstratesScience, 2004
- Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activityMolecular Cancer Therapeutics, 2004
- The proteasome: a suitable antineoplastic targetNature Reviews Cancer, 2004
- Cellular protein is the source of cross-priming antigenin vivoProceedings of the National Academy of Sciences, 2004
- Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseasesProceedings of the National Academy of Sciences, 2003
- Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory.2003
- Molecular sequelae of proteasome inhibition in human multiple myeloma cellsProceedings of the National Academy of Sciences, 2002
- T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cellsProceedings of the National Academy of Sciences, 2002